Center for Advanced Biomolecular Recognition, Korea Institute of Science and Technology, Seoul, Korea.
Endocrinol Metab (Seoul). 2022 Aug;37(4):599-607. doi: 10.3803/EnM.2022.1549. Epub 2022 Aug 19.
Accurate measurement of cortisol is critical in adrenal insufficiency as it reduces the risk associated with misdiagnosis and supports the optimization of stress dose. Comprehensive assays have been developed to determine the levels of bioactive free cortisol and their clinical and analytical efficacies have been extensively discussed because the level of total cortisol is affected by changes in the structure or circulating levels of corticoid-binding globulin and albumin, which are the main reservoirs of cortisol in the human body. Antibody-based immunoassays are routinely used in clinical laboratories; however, the lack of molecular specificity in cortisol assessment limits their applicability to characterize adrenocortical function. Improved specificity and sensitivity can be achieved by mass spectrometry coupled with chromatographic separation methods, which is a cutting-edge technology to measure individual as well as a panel of steroids in a single analytical run. The purpose of this review is to introduce recent advances in free cortisol measurement from the perspectives of clinical specimens and issues associated with prospective analytical technologies.
准确测量皮质醇对于肾上腺功能减退症至关重要,因为它降低了误诊相关的风险,并支持应激剂量的优化。已经开发了综合检测方法来确定生物活性游离皮质醇的水平,并且广泛讨论了其临床和分析功效,因为总皮质醇的水平受到皮质激素结合球蛋白和白蛋白结构或循环水平变化的影响,而这两种蛋白是人体中皮质醇的主要储存库。基于抗体的免疫测定法通常在临床实验室中使用;然而,皮质醇评估中缺乏分子特异性限制了其在表征肾上腺皮质功能方面的适用性。通过与色谱分离方法相结合的质谱,可以提高特异性和灵敏度,这是一种先进的技术,可以在单次分析运行中测量单个类固醇和类固醇组。本综述的目的是从临床标本和与前瞻性分析技术相关的问题的角度介绍游离皮质醇测量的最新进展。